Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 


      © 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

Donepezil taj Pharmaceuticals Ltd.

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Donepezil Manufacturers in India Suppliers Donepezil Exporters Distributors Donepezil api active pharmaceuticals ingredients Donepezil manufacturers Side Effects bulk drugs raw material Donepezil companies Side Effects Importers Donepezil Donepezil Exporters Donepezil exporters FDA Donepezil DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Donepezil manufacturing pharmaceutical drugs pharmaceutical intermediates Donepezil pharmaceutical chemicals pharmaceutical raw materials Donepezil active pharmaceutical ingredients Donepezil committee active pharmaceutical ingredients manufacturer Donepezil Active Pharmaceutical Ingredients manufacturer Donepezil exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Donepezil, Donepezil manufacturer India, Donepezil product, Donepezil products, Api preparation, Certificate of Analysis API manufacturer product, Donepezil anti ulcer product, Certificate of Origin COA Donepezil COS Donepezil, pharmaceutical generic, pharmaceutical drug, medical, Donepezil pharma healthcare, pharma patents, contract MSDS manufacturing Trader Donepezil pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Donepezil expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Donepezil DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Donepezil ingredients, api, HIV Donepezil, tablets, capsules, syrup & protein Donepezil powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Donepezil gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Donepezil WHO, UKMHRA Approval

   PRODUCT LIST
   Home
   API >>>
   Pharmaceuticals API List
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
 

Donepezil














 



 






 

 

HOME >> API >> API List1 >> Donepezil >> Precautions

Donepezil  CAS Number 120014-06-4


PRECAUTIONS
Donepezil CAS Number 120014-06-4

No evidence of a carcinogenic potential was obtained in an 88-week carcinogenicity study of donepezil hydrochloride conducted in CD-1 mice at doses up to 180 mg/kg/day (approximately 90 times the maximum recommended human dose on a mg/m˛ basis), or in a 104-week carcinogenicity study in Sprague-Dawley rats at doses up to 30mg/kg/day (approximately 30 times the maximum recommended human dose on a mg/m˛ basis).

Donepezil was not mutagenic in the Ames reverse mutation assay in bacteria, or in a mouse lymphoma forward mutation assay in vitro. In the chromosome aberration test in cultures of Chinese hamster lung (CHL) cells, some clastogenic effects were observed. Donepezil was not clastogenic in the in vivo mouse micronucleus test and was not genotoxic in an in vivo unscheduled DNA synthesis assay in rats.

Donepezil had no effect on fertility in rats at doses up to 10 mg/kg/day (approximately 8 times the maximum recommended human dose on a mg/m˛ basis).

Pregnancy

Pregnancy Category C: Teratology studies conducted in pregnant rats at doses up to 16 mg/kg/day (approximately 13 times the maximum recommended human dose on a mg/m˛ basis) and in pregnant rabbits at doses up to 10 mg/kg/day (approximately 16 times the maximum recommended human dose on a mg/m˛ basis) did not disclose any evidence for a teratogenic potential of donepezil. However, in a study in which pregnant rats were given up to 10 mg/kg/day (approximately 8 times the maximum recommended human dose on a mg/m˛ basis) from day 17 of gestation through day 20 postpartum, there was a slight increase in still births and a slight decrease in pup survival through day 4 postpartum at this dose; the next lower dose tested was 3 mg/kg/day. There are no adequate or well-controlled studies in pregnant women. ARICEPT® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nursing Mothers

Information Associated with Product:
DRUG DESCRIPTION
DOSAGE
SIDE EFFECTS
PRECAUTIONS >>
INTERACTION
PHARMALOGY
CONSUMER INFORMATION
 
 
PDF DOWNLOAD WORD DOCUMENT
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Taj Pharmaceuticals API Logo

Donepezil

Api Manufacturing At Taj

Acamprosate Calcium

Clomipramine Hcl

Alendronate Sodium

Clonazepam

Amitriptyline

Clopidogrel Bisulfate

Anastrozole

Danazol

Atomoxetine Hcl

Desloratadine

Balsalazide

Desmopressin Monoacetate

Bicalutamide

Divalproex Sodium

Budesonide

Dobutamine Hcl

Bupropion Hcl

Donepezil

Calcitonin

Dothiepin Hcl

Capecitabine

Entacapone

Carbamazepine

Eptifibatide

Carboplatin

Escitalopram HBr

Carisoprodol

Eszopiclone

Carvedilol

Finasteride

Cefuroxime Axetil

Flurbiprofen

Cisplatin

Fluticasone Propionate

Citalopram Hbr

Fluvoxamine Maleate

Fosphenytoin Sodium

Copyright © Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap

 

taj group logo
© 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.